EUCTR2014-000924-11-DE进行中（未招募）1 期
Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.
Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor0 个研究点目标入组 25 人开始时间: 2015年3月13日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histopathologically confirmed Mycosis fungoides or Sézary syndrome (CTCL stage = Ib according to EORTC-ISCL consensus classification2) at study entry with progressive, persistant or recurrent disease
- •Pretreatment with topical steroid and/or local PUVA, if the prior therapy is not possible anymore or if there is unsatisfactory response to PUVA or local steroid respectively. Patients with history of first line systemic treatment (interferone or bexarotene) may be included in the study too
- •Karnofsky index =70 % (according to Karnofsky DA, Burchenal JH. (1949). The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press. Page 196)
- •Life expectancy > 3 months
- •Age = 18 years
- •Adequate organ function:
- •differential blood count: hemoglobin = 10 g/dl without transfusions, leukocyte count > 3000/µl, lymphocyte count > 700/µl
- •liver enzymes = 2 x upper limit of normal (ULN)
- •serum creatinine = 1.5 mg/dl or calculate creatinine clearance = 50 ml/min,
- •Negative Pregnancy test from blood, agreement for efficient contraception in male and female patients unless infertility is documented (DMF is not approved during pregnancy)
- •Ability to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study
- •written informed consent must be given according to ICH/GCP, and national/local regulations, before patient registration and prior to any study specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •Another active malignant disease with the following exceptions:
- •Basal or squamous cell carcinoma of the skin
- •In situ carcinoma of the cervix or the skin
- •Topical chemotherapy, superficial radiotherapy, photopheresis or systemic CTCL treatment within 28 days before study therapy initiation
- •Severe systemic disease or infection at study therapy initiation
- •Prior treatment with DMF or simultaneous topical DMF treatment
- •Contraindications for treatment with DMF (known hypersensibility to the drug, severe gastrointestinal disease (like ulcerations), Alcohol abuse, other obligately liver- or nephrotoxic medication, known clinically apparent renal or hepatic insufficiency)
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •Participation in other clinical studies within 14 days before study therapy initiation
- •Pregnant or lactating patients
研究者
相似试验
已完成
2 期
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)Cutaneous T Cell LymphomaNCT02546440Universitätsmedizin Mannheim25
已完成
1 期
Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment.advanced and/or recurrent gastric cancer with peritoneal metastasisJPRN-UMIN000015812Kyushu University Hospital42
Unknown
2 期
NF-κB Inhibition in Amyotrophic Lateral SclerosisALSNCT05031351Sunnybrook Health Sciences Centre75
已完成
不适用
Evaluation of clinical utility of NF-kB Decoy Oligo coated PTA balloon catheter for arteriovenous fistula stenosis in hemodialysis shunts (AVF) Clinical trial medical device identification number: AMG0102Arteriovenous fistula stenosis in hemodialysis shuntsJPRN-UMIN000008096AnGes MG, Inc.177
进行中（未招募）
1 期
Study on the activity and safety of the FGFR inhibitor drug, INCB054828, in patients with advanced gastric adenocarcinoma, resistant to trastuzumabEUCTR2017-004522-14-ITCentro Ricerche Cliniche di Verona18